---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromicâ€™s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

secured: "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;7bvStQTJPefA7Assm/b7Ew=="
---

